AJOONI

Ajooni Biotech Share Price

₹7.05 +0.01 (0.14%)

28 Dec, 2024 01:20

SIP TrendupStart SIP in AJOONI

Start SIP

Performance

  • Low
  • ₹7
  • High
  • ₹7
  • 52 Week Low
  • ₹4
  • 52 Week High
  • ₹10
  • Open Price₹7
  • Previous Close₹7
  • Volume399,474

Investment Returns

  • Over 1 Month -8.68%
  • Over 3 Month -15.67%
  • Over 6 Month + 41%
  • Over 1 Year + 23.9%
SIP Lightning

Smart Investing Starts Here Start SIP with Ajooni Biotech for Steady Growth!

Invest Now

Ajooni Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 49.8
  • PEG Ratio
  • 0.7
  • Market Cap Cr
  • 121
  • P/B Ratio
  • 2.8
  • Average True Range
  • 0.33
  • EPS
  • 0.14
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.12
  • RSI
  • 31.54
  • MFI
  • 9.58

Ajooni Biotech Financials

Ajooni Biotech Technicals

EMA & SMA

Current Price
₹7.05
+ 0.01 (0.14%)
pointer
  • stock-down_img
  • Bullish Moving Average 1
  • stock-up_img
  • Bearish Moving Average 15
  • 20 Day
  • ₹7.46
  • 50 Day
  • ₹7.66
  • 100 Day
  • ₹7.58
  • 200 Day
  • ₹7.08

Resistance and Support

7.1 Pivot Speed
  • R3 7.44
  • R2 7.34
  • R1 7.20
  • S1 6.96
  • S2 6.86
  • S3 6.72

What's your outlook on Ajooni Biotech?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ajooni Biotech has an operating revenue of Rs. 91.01 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 4% needs improvement, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 50 which is a POOR score indicating inconsistency in earnings, a RS Rating of 58 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 94 indicates it belongs to a poor industry group of Agricultural Operations and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Ajooni Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-16 Others To consider other business matters issue of equity shares of Rs. 2/- in the ratio of 1:1 @ premium of Rs. 3/-.
2024-08-09 Quarterly Results
2024-05-20 Audited Results
2024-02-07 Quarterly Results & Others Other business matters. issue of equity shares of Rs. 2/- in the ratio of 1:1 @ premium of Rs. 3/-.
Date Purpose Remarks
2022-10-07 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.
Date Purpose Remarks
2021-03-12 Bonus Rs.0.00 issue in the ratio of 1:9 of Rs. 10/-.

Ajooni Biotech F&O

Ajooni Biotech Shareholding Pattern

26.89%
0.29%
64.69%
8.13%

About Ajooni Biotech

  • NSE Symbol
  • AJOONI
  • BSE Symbol
  • Managing Director & CFO
  • Mr. Jasjot Singh
  • ISIN
  • INE820Y01021

Similar Stocks to Ajooni Biotech

Ajooni Biotech FAQs

Ajooni Biotech share price is ₹7 As on 28 December, 2024 | 01:06

The Market Cap of Ajooni Biotech is ₹121.4 Cr As on 28 December, 2024 | 01:06

The P/E ratio of Ajooni Biotech is 49.8 As on 28 December, 2024 | 01:06

The PB ratio of Ajooni Biotech is 2.8 As on 28 December, 2024 | 01:06

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23